David J. Benjamin, Medical Oncologist at the Hoag Family Cancer Institute, reshared a post by DAVA Oncology on X:
“Thank you Dr. Jain and DAVA Oncology for the opportunity to discuss the role of maintenance avelumab in advanced urothelial carcinoma.
Identifying patient preferences (balancing survival and quality of life) may help in pairing the right individual with the right regimen.”
Quoting DAVA Oncology‘s post:
“Starting Now:
Checkpoint Inhibitors in Urothelial Carcinoma Moderated by: Tian Zhang.”
For more Updates, Follow OncoDaily.